Nord Stream 2: The Expectations of Russian Citizens from Increasing Gas Exports to Europe
Management Science and Business Decisions · 2022
DOI: 10.52812/msbd.38 ↗Kurz gefasst
Fachartikel in der Zeitschrift Management Science and Business Decisions, 2022. Verfasst von Karalina A. Tsoy. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Natural gas is one of the key exports of Russia. The country exports gas via pipelines and liquefied natural gas (LNG) via ships. In 2018, the construction of the Nord Stream 2 (NS2) project began and finished in early September 2021, despite all challenges. The purpose of the NS2 is to supply affordable natural gas to European markets while helping them improve energy security, especially for land-locked countries that are ill-suited to receive LNG. The current study aims to gauge the expectations of Russians from the increase in Russian gas exports to Europe resulting from the completion of the NS2. From the literature, some important factors were identified. Primary data was collected from the Russian citizens, and the Grey Relational Analysis model was used to analyze data and rank the key expectations of Russians from the increasing gas supply to the European consumers. The results are interesting and can help the policy-makers know the expectations of the Russian taxpayers.
Zitieren
APA
Tsoy, K. A. (2022). Nord Stream 2: The Expectations of Russian Citizens from Increasing Gas Exports to Europe. Management Science and Business Decisions. https://doi.org/10.52812/msbd.38
Vancouver
Tsoy KA. Nord Stream 2: The Expectations of Russian Citizens from Increasing Gas Exports to Europe. Management Science and Business Decisions. 2022. doi:10.52812/msbd.38
BibTeX
@article{Tsoy2022,
author = {Tsoy, Karalina A.},
title = {Nord Stream 2: The Expectations of Russian Citizens from Increasing Gas Exports to Europe},
journal = {Management Science and Business Decisions},
year = {2022},
doi = {10.52812/msbd.38}
}
EUVIMED